Document Detail


Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
MedLine Citation:
PMID:  3279966     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to 38 patients with heterozygous familial hypercholesterolaemia for 24 weeks. A dose of 40 mg per day produced a mean reduction in low density lipoprotein cholesterol of 43-45% and in triglycerides of 21-31%. Mean high density lipoprotein cholesterol increased significantly by 10-13%. There were no major differences in response whether the drug was taken in one or two doses. MK-733 was tolerated well. Adverse effects were infrequent and limited to slight increases of alanine aminotransferase, creatine phosphokinase and bilirubin. This drug appears to be a potent inhibitor of cholesterol synthesis and has produced the largest therapeutic response as monotherapy in patients with familial hypercholesterolaemia.
Authors:
M J Mol; D W Erkelens; J A Gevers Leuven; J A Schouten; A F Stalenhoef
Related Documents :
11806796 - Withdrawal of cerivastatin from the world market.
2070426 - Drug-induced myopathies.
10970046 - Antioxidant effect of dipyridamole (dip) and its derivative ra 25 upon lipid peroxidati...
2045526 - Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
23296686 - A polymer-(tandem drugs) conjugate for enhanced cancer treatment.
11074516 - Micronucleus formation induced by the combination of low doses of x-rays and antineopla...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Atherosclerosis     Volume:  69     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  1988 Feb 
Date Detail:
Created Date:  1988-04-18     Completed Date:  1988-04-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  131-7     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University Hospital, Nijmegen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Clinical Trials as Topic
Female
Heterozygote
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hyperlipoproteinemia Type II / drug therapy*,  genetics
Lovastatin / analogs & derivatives*,  therapeutic use
Male
Middle Aged
Simvastatin
Time Factors
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Degenerative spondylolisthesis, synovial cyst of the zygapophyseal joints, and sciatic syndrome: rep...
Next Document:  Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial in...